These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 19221492)

  • 1. Systemic siRNA delivery to leukocyte-implicated diseases.
    Peer D; Shimaoka M
    Cell Cycle; 2009 Mar; 8(6):853-9. PubMed ID: 19221492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Necessity is the mother of invention: an ingenious method for leukocyte-targeted delivery of siRNA in stabilized nanoparticles demonstrates a role of cyclin D1 in inflammation.
    Kakuta H
    ChemMedChem; 2008 Jul; 3(7):1024-5. PubMed ID: 18465763
    [No Abstract]   [Full Text] [Related]  

  • 3. Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies.
    Weinstein S; Toker IA; Emmanuel R; Ramishetti S; Hazan-Halevy I; Rosenblum D; Goldsmith M; Abraham A; Benjamini O; Bairey O; Raanani P; Nagler A; Lieberman J; Peer D
    Proc Natl Acad Sci U S A; 2016 Jan; 113(1):E16-22. PubMed ID: 26699502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming RNAi transduction in leukocytes using targeted and stabilized nanoparticles.
    Elfakess R; Peer D
    IDrugs; 2010 Sep; 13(9):626-31. PubMed ID: 20799145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoparticle-based delivery system for application of siRNA in vivo.
    Wang Y; Li Z; Han Y; Liang LH; Ji A
    Curr Drug Metab; 2010 Feb; 11(2):182-96. PubMed ID: 20359287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target.
    Peer D; Park EJ; Morishita Y; Carman CV; Shimaoka M
    Science; 2008 Feb; 319(5863):627-30. PubMed ID: 18239128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Progress in Non-viral RNAi-Based Delivery Strategies to Lymphocytes.
    Mizrahy S; Hazan-Halevy I; Dammes N; Landesman-Milo D; Peer D
    Mol Ther; 2017 Jul; 25(7):1491-1500. PubMed ID: 28392163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of therapeutic gene silencing in leukocyte-implicated diseases by targeted and stabilized nanoparticles: a mini-review.
    Peer D
    J Control Release; 2010 Nov; 148(1):63-68. PubMed ID: 20624432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A daunting task: manipulating leukocyte function with RNAi.
    Peer D
    Immunol Rev; 2013 May; 253(1):185-97. PubMed ID: 23550647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cutting-edge technologies of siRNA delivery and their application in clinical trials.
    Lee K; Jang B; Lee YR; Suh EY; Yoo JS; Lee MJ; Lee JY; Lee H
    Arch Pharm Res; 2018 Sep; 41(9):867-874. PubMed ID: 30136248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. siRNA delivery systems for cancer treatment.
    Oh YK; Park TG
    Adv Drug Deliv Rev; 2009 Aug; 61(10):850-62. PubMed ID: 19422869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Progress of Small Interfering RNA Delivery on the Market and Clinical Stage.
    Guo F; Li Y; Yu W; Fu Y; Zhang J; Cao H
    Mol Pharm; 2024 May; 21(5):2081-2096. PubMed ID: 38630656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in siRNA delivery.
    Sarisozen C; Salzano G; Torchilin VP
    Biomol Concepts; 2015 Dec; 6(5-6):321-41. PubMed ID: 26609865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent progress in development of siRNA delivery vehicles for cancer therapy.
    Kim HJ; Kim A; Miyata K; Kataoka K
    Adv Drug Deliv Rev; 2016 Sep; 104():61-77. PubMed ID: 27352638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid-based nanocarriers for delivery of small interfering RNA for therapeutic use.
    Parashar D; Rajendran V; Shukla R; Sistla R
    Eur J Pharm Sci; 2020 Jan; 142():105159. PubMed ID: 31747618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in RNAi therapeutic delivery to leukocytes using lipid nanoparticles.
    Ramishetti S; Landesman-Milo D; Peer D
    J Drug Target; 2016 Nov; 24(9):780-786. PubMed ID: 27030014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multifunctional pH-Sensitive Amino Lipids for siRNA Delivery.
    Gujrati M; Vaidya A; Lu ZR
    Bioconjug Chem; 2016 Jan; 27(1):19-35. PubMed ID: 26629982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted delivery systems of small interfering RNA by systemic administration.
    Kawakami S; Hashida M
    Drug Metab Pharmacokinet; 2007 Jun; 22(3):142-51. PubMed ID: 17603214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonviral in vivo delivery of therapeutic small interfering RNAs.
    Aigner A
    Curr Opin Mol Ther; 2007 Aug; 9(4):345-52. PubMed ID: 17694447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanocarriers: a tool to overcome biological barriers in siRNA delivery.
    Kumari A; Kumar V; Yadav SK
    Expert Opin Biol Ther; 2011 Oct; 11(10):1327-39. PubMed ID: 21682658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.